Introduction
============

Retinitis pigmentosa (RP) is an inherited, degenerative eye disease that causes severe vision impairment and often blindness. RP has a prevalence of about 1:3,000--1:7,000 and is the most frequent form of inherited retinal degeneration, without apparent ethnic or racial distinctions \[[@r1]-[@r3]\]. RP is a clinically and genetically heterogeneous disease. Clinically, the age of onset and the rate of progression are different. Symptoms usually emerge as night blindness and progress to legal blindness. Genetically, many different mutations in different genes cause similar consequences, yet other mutations in the same gene may cause different diseases \[[@r4]\].

There are dominant, recessive, and X-linked forms of inheritance. Some cases are sporadic and lack a family history of the disease. RP may occur alone or as part of a more complex syndrome \[[@r2]\]. Since the first disease-causing gene (*RHO;* gene ID: 6010, OMIM: [180380](http://www.ncbi.nlm.nih.gov/omim/?term=180380)) was discovered in 1990, more than 60 genes that cause RP have been reported ([RetNet](https://sph.uth.edu/RetNet/)) \[[@r5]\]. Most genes were only a small proportion of cases. The *RHO* gene accounts for approximately 25% of autosomal dominant RP (adRP) in Americans \[[@r6],[@r7]\]. The rate of *RHO* mutations in Koreans, Japanese, and Chinese is lower than in Americans \[[@r8]-[@r10]\].

In this study, we had collected 300 probands with RP in an outpatient setting. In the follow-up genetic study, we identified eight mutations in the *RHO* gene that is responsible for the disease.

Methods
=======

Patients and clinical data
--------------------------

300 probands enrolled in this study were come maily from Hebei Province, Henan province and Shanxi province. Probands include 171 males and 129 females. Patients come to our hospital from ages 5 to 72 years. After probands were diagnosed RP, their family history inquiry were collected in detail and their family members were recruited further. The probands enrolled in this study were from Hebei Province, China. Clinical examination, peripheral blood collection, and DNA extraction were performed at the Department of Ophthalmology, Hebei Ophthalmic Hospital. Peripheral blood was drawn after register and preserved at -80 °C Ultra-low temperature freezer prior to use. Genomic DNA was isolated with DNA extraction kit (DP332, Tiangen, Beijing, China). Informed consent was obtained from all participants in accordance with the Declaration of Helsinki, the Institutional Review Board, and Ethics Committee of Hebei Province. Clinical data for the subjects were ascertained with detailed ocular examinations. In addition, physical examinations were performed to exclude systemic diseases.

In the mutation analysis, coding exons of *RHO* were amplified with PCR using a set pair of primers \[[@r8]\]. The PCR products were sequenced on an ABI3730 Automated Sequencer (PE Biosystems, Foster City, CA). Briefly, PCR amplification conditions were: Reaction Mixture Set Up (50 μl); 2 μl (40 ng/ml) of DNA, 1.5 μl (10 pM) of each exon primer, 20 μl of water, and 25 μl of PCR mix (2× EasyTaq PCR SuperMix, TransGen, Beijing, China) in a final reaction volume of 50 μl. Thermal cycling conditions were: an initial denaturation step at 95 °C for 5 min, 36 cycles (30 s at 95 °C, 30 s at 58 °C, and 30 s at 72 °C) and a final 10 min 72 °C extension. The PCR products were sequenced on an ABI3730 automated sequencer (PE Biosystems, Foster City, CA).

Results
=======

Clinical findings
-----------------

All probands showed typical RP disease ([Table 1](#t1){ref-type="table"}). The 300 probands included 40 with adRP, 38 with autosomal recessive RP (arRP), and 222 sporadic cases. The physical examinations excluded systemic disorders in all patients.

###### The clinical features of probands from the eight families.

  **Proband/Family**   **Age/Sex**   **Mutation**   **Onset of blindness**   **BCVA**    **Fundus^a^**   **ERG**
  -------------------- ------------- -------------- ------------------------ ----------- --------------- --------------------
  III:1/Family 12      24 y/F        p.R21C         16 y                     0.25/0.25   No              No rod responses
  II:4/Family 245      39 y/F        p.T92I         Early Childhood          0.10/0.10   YES             No rod responses
  III:1/Family 30      43 y/M        p.C110S        Early Childhood          0.12/0.12   YES             Data not available
  II:7/Family 13       42 y/F        p.G182V        Early Childhood          0.15/0.12   YES             No rod responses
  II:5/Family 22       48 y/F        p.C187G        Early Childhood          0.30/0.30   YES             No rod responses
  III:3/Family 7       42 y/F        c.409-426del   25 y                     0.15/0.12   YES             No rod responses
  II:5/Family 171      39 y/M        p.Y178C        Early Childhood          0.20/0.30   YES             No rod responses
  III:1/Family 21      27 y/M        p.P347L        Early Childhood          0.40/0.30   YES             No rod responses

Abbreviations: BCVA, best corrected visual acuity; ERG, electroretinogram; ^a^,bone spicule pigment deposits.

Mutation analysis
-----------------

Sequence analysis of the coding region of *RHO* was performed in the probands. Eight heterozygous nucleotide changes were detected in eight of the 300 probands with RP ([Figure 1](#f1){ref-type="fig"}, [Figure 2](#f2){ref-type="fig"}). p.R21C, p.C110S, p.G182V, p.C187G, c.409--426delGTGGTGGTGTGTAAGCCC, and p.P347L were found in six autosomal dominant families. p.T92I and p.Y178C were found in two isolated cases. The eight mutations include six novel mutations (p.R21C, p.T92I, p.C110S, p.G182V, p.C187G, and c.409--426delGTGGTGGTGTGTAAGCCC) and two known mutations (p.Y178C and p.P347L). Of the eight mutations, seven were missense changes, and one was a small deletion ([Figure 3](#f3){ref-type="fig"}). Missense mutations were predicted to be pathogenic with [SIFT](http://sift.jcvi.org/www/SIFT_seq_submit2.html) and [Polyphen-2](http://genetics.bwh.harvard.edu/pph2/) prediction software ([Table 2](#t2){ref-type="table"}). These mutations were not found in 100 control individuals from the same ethnic background. The mutation frequencies were 15% (6/40) for adRP, 0.9% (2/222) for sporadic RP, and 2.7% (8/300) in total. No mutation was detected in families with arRP.
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###### Prediction of the functional impact of missense mutations.

  Mutation   SIFT   Polyphen-2 (HumDiv)   Polyphen-2 (HumVar)
  ---------- ------ --------------------- ---------------------
  R21C       0.01   Probably damaging     Probably damaging
  T92I       0.07   Possibly damaging     Possibly damaging
  C110S      0      Probably damaging     Probably damaging
  G182V      0      Probably damaging     Probably damaging
  C187G      0      Probably damaging     Probably damaging
  Y178C      0      Probably damaging     Probably damaging
  P347L      0      Probably damaging     Probably damaging

Discussion
==========

In this study, 300 families with RP in an outpatient setting in the past 2 years were collected consecutively. In the follow-up genetic study, we identified eight mutations in the *RHO* gene. The results show that *RHO* mutations accounted for a high proportion (15%, 6/40) in Chinese patients with adRP. *RHO* mutations in arRP and sporadic RP are not common.

Up to now, more than 160 mutations of *RHO* have been found in different racial and ethnic populations ([HGMD](http://www.hgmd.cf.ac.uk/ac/index.php)). Studies show that mutations in this gene are responsible for approximately 25% of adRP in American patients. The P23H mutation occurs most frequently in American patients but has not been reported in patients with RP in other ethnic populations \[[@r6],[@r10]\]. P347L and Y178C mutations have been reported in several ethnic populations \[[@r6],[@r8]-[@r13]\].

The proportion of *RHO* mutations in Asia is lower than in the United States and Europe. The proportion of *RHO* mutations in Chinese patients was 2.0--5.6%, 2.0% in Koreans, 2.0% in Japanese, and 2.0% in Indians \[[@r8]-[@r10],[@r14]\].

In conclusion, our study provides useful material for evaluating the proportion of *RHO* mutations in Chinese patients with RP. We revealed the spectrum and frequency of *RHO* mutations in Chinese patients with RP. *RHO* mutations were found in 2.7% of the Chinese patients.

Dr. Minglian Zhang (<zhangminglian001@126.com>) and Dr. Jialiang Zhao (<zhaojialiang1234@aliyun.com>) are co-corresponding authors.
